173192-39-7

Basic information

• Product Name: (±)-3-(2-(benzyloxy)acyl)dihydrofuran-2(3H)-one
• Synonyms: (±)-3-(2-(benzyloxy)acyl)dihydrofuran-2(3H)-one
• CAS NO: 173192-39-7
• Molecular Weight: 234.252
• Mol File: 173192-39-7.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: (±)-3-(2-(benzyloxy)acyl)dihydrofuran-2(3H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: (±)-3-(2-(benzyloxy)acyl)dihydrofuran-2(3H)-one(173192-39-7)
• EPA Substance Registry System: (±)-3-(2-(benzyloxy)acyl)dihydrofuran-2(3H)-one(173192-39-7)

Safety Data

• Hazardous Substances Data: 173192-39-7(Hazardous Substances Data)

Upstream product

• 32122-09-1 ethyl benzyloxyacetate 
• 96-48-0 4-butanolide 
• 100-51-6 benzyl alcohol 

Downstream Products

• 177987-29-0 (3S)-3-[(1S)-2-(benzyloxy)-1-hydroxyethyl]-4,5-dihydrofuran-2(3H)-one 
• 156928-09-5 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-ol 
• 725264-61-9 (1'R,2R)-2-[2'-benzyloxy-1'-hydroxyethyl]-4-butanolide 

Relevant articles and documents

Ru-catalyzed asymmetric transfer hydrogenation of α-acyl butyrolactone via dynamic kinetic resolution: Asymmetric synthesis of bis-THF alcohol intermediate of darunavir

The Ru-catalyzed enantio- and diastereoselective dynamic kinetic resolution of α-(benzyloxy/benzoyloxy)acyl-γ-butyrolactones has been examined via transfer hydrogenation. Employing the in situ prepared (R,R)-Ru-FsDPEN catalyst, the transfer hydrogenation of using formic acid/triethylamine at rt gave the corresponding (S)-3-((S)-2-(benzyloxy/benzoyloxy)-1-hydroxyethyl)dihydrofuran-2(3H)-one with good to excellent diastereo- and enantioselectivity. One of the resulting hydrogenation product prepared on gram scales was utilized for the synthesis of (3R,3aS,6aR)-hexahydrofuro[2,3–b]furan-3-ol (1), a key synthetic intermediate of various HIV protease inhibitors such as darunavir with excellent enantio- (95% ee) and diastereoselectivities (dr 95:5).

Enzymatic process for the preparation of butyrolactones

The invention relates to a process for the preparation of a compound of formula wherein R1 is selected from the group consisting of hydrogen, C2-11-acyl, C4-9-cycloalkanoyl, aryl, aralkyl, aroyl, hetaryl, hetaralkyl and hetaroyl, comprising a biotransformation of a compound of formula wherein R1 is as defined above, wherein said biotransformation is carried out using a polypeptide having aldo-keto reductase activity or a microorganism containing same.

Pyrrolopyrazolopyrimidine compound and medicine comprising the same as active ingredient

The invention relates to compounds represented by the following general formula (1): STR1 wherein R1 represents an alkyl group, R2 represents an amino group, alkyl group or the like, and R3 represents a nitro group, amino group, heterocyclic group, alkylsulfonylamino group or the like, or salts thereof, medicines comprising such a compound, a preparation process of the compounds, and intermediates useful for preparation thereof. The compounds (1) are useful for the prevention and treatment of a respiratory disease.